Our commercial momentum continues to grow in the second quarter of this year with strong launch progress in both Crysvita and Mepsevii in three major territories -- throughout the world. Yesterday, we submitted our new drug application for UX007 or triheptanoin for the treatment of long chain fatty acid oxidation disorders. We have relentlessly focused on advancing UX007 through the clinic and into regulatory review, in order to get this therapy to patients as quickly as possible.